Sareum Holdings plc (AIM:SAR)

Market Cap	24.85M -3.0%
Revenue (ttm)	n/a
Net Income	-4.44M
EPS	-0.04
Shares Out	138.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,498
Average Volume	154,645
Open	17.60
Previous Close	17.50
Day's Range	17.21 - 18.69
52-Week Range	9.50 - 29.00
Beta	-1.02
RSI	52.92
Earnings Date	Mar 20, 2026

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SAR